Response to Pembrolizumab in a Patient with Relapsing Thymoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Response to Pembrolizumab in a Patient with Relapsing Thymoma

Published:2016-12 Issue:12 Volume:11 Page:e147-e149
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Zander Thilo,Aebi Stefan,Rast Anna Christina,Zander Andrea,Winterhalder Ralph,Brand Christoph,Diebold Joachim,Gautschi Oliver

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade;Weber;Semin Oncol,2010

2. Diffuse high intensity PD-L1 staining in thymic epithelial tumors;Padda;J. Thorac Oncol,2016

3. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma;Katsuya;Lung Cancer,2015

4. A phase II study of pembrolizumab in patients with recurrent thymic;Giaccone;J Clin Oncol,2016

5. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies;Naidoo;Ann Oncol,2015

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abnormal Cellular Populations Shape Thymic Epithelial Tumor Heterogeneity and Anti‐Tumor by Blocking Metabolic Interactions in Organoids;Advanced Science;2024-09-11

2. Immune checkpoint inhibitor myocarditis in thymic epithelial tumors: a case report and literature review;Translational Cancer Research;2024-02

3. Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review;Biomedicines;2023-10-08

4. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial;ESMO Open;2023-06

5. Fatal triad of checkpoint inhibitors: Pembrolizumab induced myasthenia gravis with myositis and myocarditis in a patient with thymoma;Neurology Asia;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3